turn ideas into companies.
“As part of the D2P process, we did a lot of research and interviewing of folks in the industry to discover where the needs were,” he says. “The university’s resources and our efforts there helped to clarify the focus of the company.”
In the coming months, Stem Pharm will focus on expanding its product line and forming strategic partnerships, Murphy says.
“Launching a couple of new products that relate to this idea of tissue self-assembly for drug screening applications is critical,” he says. “In addition to that, forging partnerships with companies that can use Stem Pharm technologies to deliver cell therapies more effectively will be an important milestone.”
